La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
West Pharmaceutical Services Gestion
Gestion contrôle des critères 4/4
Le PDG West Pharmaceutical Services' est Eric Green, nommé en Apr2015, a un mandat de 9.33 ans. La rémunération annuelle totale est $ 9.40M, composée du salaire de 12.1% et des bonus 87.9%, y compris les actions et options de la société. détient directement 0.23% des actions de la société, d'une valeur de $ 50.44M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 9.3 ans.
Informations clés
Eric Green
Directeur général
US$9.4m
Rémunération totale
| Pourcentage du salaire du PDG | 12.1% |
| Durée du mandat du directeur général | 9.4yrs |
| Propriété du PDG | 0.2% |
| Durée moyenne d'occupation des postes de direction | 4.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9.3yrs |
Mises à jour récentes de la gestion
Recent updates
Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20
A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
| Sep 30 2019 | n/a | n/a | US$230m |
| Jun 30 2019 | n/a | n/a | US$229m |
| Mar 31 2019 | n/a | n/a | US$219m |
| Dec 31 2018 | US$5m | US$880k | US$207m |
| Sep 30 2018 | n/a | n/a | US$155m |
| Jun 30 2018 | n/a | n/a | US$151m |
| Mar 31 2018 | n/a | n/a | US$133m |
| Dec 31 2017 | US$5m | US$824k | US$151m |
Rémunération vs marché: La rémunération totale de Eric ($USD 9.40M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).
Rémunération et revenus: La rémunération de Eric a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Eric Green (54 yo)
9.4yrs
Titularisation
US$9,395,896
Compensation
Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 9.4yrs | US$9.40m | 0.23% $ 52.2m | |
| Senior VP & CFO | 6.3yrs | US$3.64m | 0.0095% $ 2.1m | |
| Senior VP & CTO | 3.8yrs | US$1.67m | 0.0039% $ 888.9k | |
| Senior VP | 3.8yrs | US$1.49m | 0.0019% $ 421.9k | |
| Senior VP & Chief Commercial Officer | 4.8yrs | US$1.53m | 0.0067% $ 1.5m | |
| VP, Chief Accounting Officer & Corporate Controller | 4.9yrs | pas de données | 0.0018% $ 406.1k | |
| Head of Investor Relations | no data | pas de données | pas de données | |
| Vice President of Global Communications | no data | pas de données | pas de données | |
| Senior VP of Strategy & Corporate Development | less than a year | pas de données | pas de données | |
| Chief Human Resources Officer & Senior VP | 8.9yrs | US$1.14m | 0.0090% $ 2.0m | |
| Senior VP and Chief Quality & Regulatory Officer | 2.3yrs | pas de données | pas de données | |
| President of Contract Manufacturing | less than a year | pas de données | pas de données |
4.3yrs
Durée moyenne de l'emploi
54yo
Âge moyen
Gestion expérimentée: L'équipe de direction de WST est considérée comme expérimentée (ancienneté moyenne 4.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 9.3yrs | US$9.40m | 0.23% $ 52.2m | |
| Independent Director | 10.6yrs | US$359.35k | 0.024% $ 5.3m | |
| Independent Director | 4.6yrs | US$330.66k | 0.0034% $ 755.8k | |
| Independent Director | 16.9yrs | US$390.35k | 0.059% $ 13.4m | |
| Independent Director | 13.6yrs | US$378.23k | 0.056% $ 12.6m | |
| Independent Director | 13.6yrs | US$377.01k | 0.059% $ 13.3m | |
| Lead Independent Director | 8yrs | US$367.44k | 0.012% $ 2.7m | |
| Independent Director | 2.2yrs | US$331.46k | 0.0015% $ 333.9k | |
| Independent Director | 12.6yrs | US$362.83k | 0.040% $ 9.1m | |
| Independent Director | 7.3yrs | US$333.45k | pas de données | |
| Honorary Director | no data | pas de données | pas de données | |
| Independent Director | 3.1yrs | US$321.43k | 0.00087% $ 196.3k |
9.3yrs
Durée moyenne de l'emploi
63yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de WST sont considérés comme expérimentés (ancienneté moyenne 9.3 ans).